Reminyl impaired cognitive function?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J's Alzheimer's agent Reminyl (galantamine) yielded a higher mortality rate versus placebo in two studies in mild cognitive impairment, prompting a review by FDA and foreign health authorities, J&J says Jan. 21. Of the approximately 2,000 patients in the GAL-INT-11 and GAL-INT-18 studies, "20 deaths due to various causes were reported during the double-blind portion of the two pivotal studies, with 15 occurring in subjects randomized to galantamine and five occurring in patients receiving placebo," the company reports. Neither trial showed efficacy in mild cognitive impairment - J&J is no longer pursuing an indication in the condition...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.